Patients Are Willing to Wait for Rapid Sexually Transmitted Infection Results in a University Student Health Clinic

Gettinger, Jesse; Wagoner, Nicholas Van; Daniels, Brice; Boutwell, Alexander; Pol, Barbara Van Der

doi:10.1097/olq.0000000000001083

Cited by 20 publications

(24 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, in the United States, Gettinger and colleagues used the binx health io assay, a 30-minute test, and sample-first approach that minimized wait times, as the sample testing began before patient interaction with a clinical provider. 26 In this highly efficient university student health clinic, waiting for results added an average of 11 minutes to the total clinical visit. In contrast to the Harding-Esch findings, in this study, 83% of the 108 participants were willing to wait for their results.…”

Section: Resultsmentioning

confidence: 99%

“… 16 At the patient level, new screening approaches that lower diagnostic running time and decrease the time between receiving results and treatment can help to improve patient motivation to seek testing. 15 , 20 , 21 , 26 When implementing new screening processes, patient characteristics have a large effect on acceptance and willingness to seek testing. Studies in this review showed that self-sampling is generally acceptable to patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Systematic Review of New Approaches to Sexually Transmitted Infection Screening Framed in the Capability, Opportunity, Motivation, and Behavior Model of Implementation Science

Footman¹,

Dagama²,

Smith

et al. 2021

Sexual Trans Dis

Self Cite

View full text Add to dashboard Cite

Chlamydia and gonorrhea are 2 of the most common bacterial sexually transmitted infections (STIs) worldwide. Rising chlamydia and gonorrhea rates along with increased closing of STI clinics has led many to seek STI testing in clinical settings such as urgent cares and walk-in clinics. However, with competing priorities, providing effective and efficient STI care can be difficult in these settings. This has left a growing need for the implementation of novel STI screening programs in other clinical settings. This review summarizes previous studies that have evaluated the clinical implementation of chlamydia and gonorrhea screening programs in these settings. Literature from January 2015 to February 2020 regarding the implementation or evaluation of STI screening programs in clinical settings was reviewed. Constructs from the Capability, Opportunity, Motivation, and Behavior model were used to organize results, as this model can aid in identifying specific strategies for behavior/process change interventions. We found that multiple STI screening programs have been implemented and evaluated in 5 different countries and multiple health care facilities including sexual health clinics, urgent cares, walk-in clinics, and university health clinics. When implementing new STI screening programs, sample-first, test-and-go services and molecular point-of-care (POC) testing approaches were found to be effective in increasing screening and reducing costs and time to treatment. At the health care systems level, these programs can help reduce STI screening costs and generate additional revenue for clinics. At the provider level, clear communication and guidance can help clinical and administrative staff in adopting new screening programs. Finally, at the patient level, new programs can reduce time to treatment and travel costs in visiting clinics multiple times for testing and treatment services.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A Systematic Review of New Approaches to Sexually Transmitted Infection Screening Framed in the Capability, Opportunity, Motivation, and Behavior Model of Implementation Science

Footman¹,

Dagama²,

Smith

et al. 2021

Sexual Trans Dis

Self Cite

View full text Add to dashboard Cite

show abstract

“…The binx health io CT/NG has been implemented in a small number of clinical settings, however, available reports show the test being implemented in research-use only scenarios in the USA [ 43 , 44 ] and publications (to-date of this review) reporting implementation in the UK do not report clinical and other health-related outcomes [ 45 ]. The Cepheid CT/NG GeneXpert has been implemented and evaluated for multiple outcomes measures in many settings around the world.…”

Section: Resultsmentioning

confidence: 99%

“…In Table 4 , in addition to the Cepheid CT/NG GeneXpert studies included in Table 3 , we report on a wider literature of stakeholder values for implementation of POCTs, including reports of the binx health io CT/NG. Studies reporting implementation of the binx CT/NG in a sexual health specialist service and a University student health clinic (outreach service) in the USA were restricted to implementation without results delivery; at the time of the studies the test was not yet FDA approved [ 43 , 44 , 73 ]. Publication of a UK-based project tracing implementation into routine care did not include assessment of clinical outcomes [ 73 ].…”

Section: Resultsmentioning

confidence: 99%

“…Publication of a UK-based project tracing implementation into routine care did not include assessment of clinical outcomes [ 73 ]. Nevertheless, the available studies (albeit limited to the USA and UK) have shown implementation processes of this CT/NG POCT to be highly acceptable to patients [ 43 , 44 ] and healthcare workers [ 44 , 45 , 73 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Molecular chlamydia and gonorrhoea point of care tests implemented into routine practice: Systematic review and value proposition development

2021

View full text Add to dashboard Cite

Background Sexually Transmitted Infections, including Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT), continue to be a global health problem. Increased access to point-of-care-tests (POCTs) could help detect infection and lead to appropriate management of cases and contacts, reducing transmission and development of reproductive health sequelae. Yet diagnostics with good clinical effectiveness evidence can fail to be implemented into routine care. Here we assess values beyond clinical effectiveness for molecular CT/NG POCTs implemented across diverse routine practice settings. Methods We conducted a systematic review of peer-reviewed primary research and conference abstract publications in Medline and Embase reporting on molecular CT/NG POCT implementation in routine clinical practice until 16th February 2021. Results were extracted into EndNote software and initially screened by title and abstract by one author according to the inclusion and exclusion criteria. Articles that met the criteria, or were unclear, were included for full-text assessment by all authors. Results were synthesised to assess the tests against guidance criteria and develop a CT/NG POCT value proposition for multiple stakeholders and settings. Findings The systematic review search returned 440 articles; 28 were included overall. The Cepheid CT/NG GeneXpert was the only molecular CT/NG POCT implemented and evaluated in routine practice. It did not fulfil all test guidance criteria, however, studies of test implementation showed multiple values for test use across various healthcare settings and locations. Our value proposition highlights that the majority of values are setting-specific. Sexual health services and outreach services have the least overlap, with General Practice and other non-sexual health specialist services serving as a “bridge” between the two. Conclusions Those wishing to improve CT/NG diagnosis should be supported to identify the values most relevant to their settings and context, and prioritise implementation of tests that are most closely aligned with those values.

show abstract

Evaluation of the Performance of a Point-of-Care Test for Chlamydia and Gonorrhea

et al. 2020

Self Cite

View full text Add to dashboard Cite

IMPORTANCERates of chlamydial and gonococcal infection continue to increase in the United States, as do the associated costs of untreated infections. Improved diagnostic technologies that support testing and treating in 1 clinical visit are critical to advancing efforts to control the rates of chlamydial and gonococcal infection. OBJECTIVE To evaluate the clinical performance of a point-of-care (POC) molecular diagnostic assay for the detection of chlamydia and gonorrhea.

show abstract

Patients Are Willing to Wait for Rapid Sexually Transmitted Infection Results in a University Student Health Clinic

Cited by 20 publications

References 13 publications

A Systematic Review of New Approaches to Sexually Transmitted Infection Screening Framed in the Capability, Opportunity, Motivation, and Behavior Model of Implementation Science

A Systematic Review of New Approaches to Sexually Transmitted Infection Screening Framed in the Capability, Opportunity, Motivation, and Behavior Model of Implementation Science

Molecular chlamydia and gonorrhoea point of care tests implemented into routine practice: Systematic review and value proposition development

Evaluation of the Performance of a Point-of-Care Test for Chlamydia and Gonorrhea

Contact Info

Product

Resources

About